Sartorius Raises Lab Outlook and Scraps Its Divisional Structure, but Warns the Strong Q3 Is Not a New Run Rate
Nine-month 2026 results call for Sartorius AG and Sartorius Stedim Biotech, October 22, 2026
One Sartorius: a new operating model and a simpler reporting structure
The most consequential news was not in the numbers. CEO Michael Grosse said Sartorius will stop managing the business in "separate divisional silos" and will move to a functional model. Alexandra Gatzemeyer becomes Chief Commercial Officer, responsible for account management, marketing and customer and technical services across the group. Rene Faber becomes Chief Product Officer, covering R&D, product management, technical sales and manufacturing, while keeping his role as CEO of Sartorius Stedim Biotech. Grosse will personally lead a new global operations function. The stated aim is "one company with one face to the customers." Grosse said the new organization began forming in the summer and will be formalized in early 2027.
External reporting changes with it. From the first quarter of 2027, Bioprocess Solutions becomes a Bioprocessing Solutions segment that exactly mirrors Sartorius Stedim Biotech, and Lab Products & Services becomes a Research Solutions segment covering everything outside the French-listed subsidiary. A reconciliation line will mainly capture intercompany eliminations. This removes the revenue and EBITDA gaps between the parent's bioprocess division and the subsidiary that stem from product allocations, a real modeling nuisance. The nine-month figures show it: the division reported underlying EBITDA of EUR 714 million at a 32.3% margin, against EUR 716 million at 31.3% for Sartorius Stedim Biotech.
Management says the restatement is limited and group revenue and underlying EBITDA are unaffected. Full-year 2026 will be reported on the existing structure with pro forma 2025 and 2026 figures under the new one, and 2027 guidance will use the new segments. Asked whether the change leaves any reason to keep the subsidiary listed, CFO Florian Funck was direct: "If your question was in the direction of a delisting, this is not in the cards." The company also said it will publish full-year results and both annual reports together on February 23, and that IFRS 18 from 2027 will reshuffle the P&L presentation without altering underlying EBITDA as the central KPI.
Lab division beats and guidance moves up, with a clear warning on pull-forward
Lab Products & Services was the upside surprise. Operational sales rose 8.3% in constant currencies over nine months, or 7.5% after tariff compensation, with MATTEK adding about 2 percentage points. Management now expects growth around the upper end of its 2% to 6% range. The underlying EBITDA margin guide rises to slightly above 21% from slightly below 21%. Growth was led by bioanalytics, consumables and services, helped by improving biotech funding and a gradual release of customer CapEx. An analyst from KeyBanc noted lab products growth of about 14% in the quarter and over 20% in Asia Pacific, with China leading.
Management repeatedly cautioned against extrapolating. Funck said part of the third quarter "reflects demand pull forward and timing effects" after a prolonged period of subdued customer investment, "and should therefore not be extrapolated as a new run rate." Grosse added that Q4 faces a demanding comparison base in both divisions and that MATTEK is now in the organic baseline. Gatzemeyer declined to quantify the pull-forward but denied that a large one-off tender flattered the quarter. She described the strength as broad across segments and geographies. Her read on U.S. academia and government was restrained: performance has "slightly improved," but not to the levels of prior years.
AI-driven drug discovery: early evidence, with the customer mix not yet AI-native
Management pitched AI-enabled drug discovery as a growth driver for Octet and Incucyte, the latter with an NVIDIA collaboration. Gatzemeyer gave a useful description of where demand actually comes from. Buyers are biopharma and academic customers, not AI-native companies, who run more experiments per instrument and feed the data into models. The models propose new targets, which then "generate more work in the wet lab." That supports instruments, consumables, software and services. On the bioprocess side, Faber said process development teams are preparing for a larger number of candidates and a higher success rate, which plays to high-throughput development systems. The effect is still early and unquantified, but the mechanism is plausible.
Bioprocessing: steady recovery, and a candid answer on the 5,000-liter bioreactor
Bioprocess Solutions grew 8.1% operationally and 6.8% including tariff compensation. Consumables grew at a double-digit rate, and the nonrecurring business grew year on year, which management cited as evidence that "the bottom is behind us." Advanced therapies orders that slipped in Q2 are still expected either late 2026 or in 2027. Management expects slight nonrecurring growth for the year, with 2027 commentary deferred to guidance.
UBS's Matthew Weston raised the main investor debate: whether a competitor's 5,000-liter single-use bioreactor will cost Sartorius share in U.S. facility fit-outs. Faber did not concede the point. He said recent platform wins include conversions of competitor bioreactors, and that with higher titers and intensification, volumes of 2,000 liters and below should cover most customer demand. He called the 5,000-liter push "a quick increase in capacity for the older legacy low titer processes, which we don't believe is the future." That is a clear strategic bet, and it carries risk if large-scale legacy demand proves stickier than Sartorius assumes. Faber also said the company is focused on low-volume, high-mix pipelines, while acknowledging that blockbuster stainless-steel facilities remain a meaningful consumables market.
On U.S. investment, Grosse repeated that nonrecurring orders are expected in late 2027 and 2028. He said recent brownfield additions are not attributable to reshoring and that Sartorius does not yet see "a very structural demand." The company expects regional or even global overcapacity to result from these projects.
Financials: margin expansion, strong cash conversion, deleveraging
Group operational sales growth was 8.1% in constant currencies for nine months, or 6.9% after customer compensation. Group underlying EBITDA rose 6.9% to EUR 828 million, with the margin up 50 basis points to 30.2%, driven by volume and operating leverage that outweighed adverse mix and growth investment. Underlying net profit rose about 7% to EUR 260 million, or EUR 3.76 per ordinary share. Reported net profit rose 51% to EUR 188 million on lower extraordinary costs.
Free cash flow rose 55% to EUR 310 million on operating cash flow of EUR 562 million and lower CapEx. Net debt fell to EUR 3.68 billion, nearly EUR 200 million below a year ago, and leverage improved to 3.3x underlying EBITDA. The equity ratio rose to 42.8%. The full-year CapEx ratio guide was trimmed to about 12% from 12.5%, and year-end leverage is still expected slightly above 3x.
Sartorius Stedim Biotech grew operational sales 7.8% in constant currencies (6.5% after compensation) to EUR 2.29 billion. Underlying EBITDA rose 4.8% to EUR 716 million at a 31.3% margin. A higher brand name fee was a 25 basis point drag, so underlying margin progress was stronger than the reported 20 basis point gain. Free cash flow rose 58.5% to EUR 264 million, and leverage fell to 2.26x. The subsidiary's CapEx guide was lowered to about 13% from 13.3%.
Tariffs and FX: noise that management is now stripping out
Tariff surcharges flipped from a tailwind to a headwind in Q3 as rates fell from about 15% to about 10%, costing roughly 40 basis points of growth for the group and 50 basis points for lab products. Sartorius has received EUR 31 million of the roughly EUR 40 million in U.S. tariff refunds it claimed and expects the remaining EUR 9 million by year-end, with timing uncertain. Customer compensation cut nine-month growth by about 120 basis points. Net of surcharges and compensation, profitability is unaffected. Management guides to group growth around the midpoint of the 5% to 9% operational range. After compensation it expects the lower half of the range for the group and bioprocess division, and the upper end for lab products. FX is a headwind of slightly more than 1 point for the year but a tailwind of just under 2 points in Q4.
China and competition
Asia Pacific was the strongest region, up 11% in constant currencies with both divisions in double digits. Grosse described healthy pipeline-driven demand across biotech, large biopharma, academia and some CDMOs. Local competitors are concentrated in local-for-local production and in less differentiated product segments, and he saw no major change in their position.